Utility and Appropriateness of the Fatty Liver Inhibition of Progression (FLIP) Algorithm and Steatosis, Activity, and Fibrosis (SAF) Score in the Evaluation of Biopsies of Nonalcoholic Fatty Liver Disease

被引:485
作者
Bedossa, Pierre [1 ]
机构
[1] FLIP Pathol Consortium, Paris, France
关键词
PLACEBO-CONTROLLED TRIAL; MORBIDLY OBESE-PATIENTS; CHRONIC HEPATITIS-C; SAMPLING VARIABILITY; FOLLOW-UP; STEATOHEPATITIS; PIOGLITAZONE; PATHOLOGY; SYSTEM; AGREEMENT;
D O I
10.1002/hep.27173
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Biopsy is still the gold standard for the diagnosis of nonalcoholic steatohepatitis but the definition may vary among pathologists, a drawback especially in evaluation of biopsies for clinical trials. We previously developed a scoring system (steatosis, activity, fibrosis [SAF]) allowing the use of an algorithm (fatty liver inhibition of progression [FLIP]) for the classification of liver injury in morbid obesity. The aim of this study was to determine whether the use of the SAF score and FLIP algorithm can decrease interobserver variations among pathologists. In a first session, pathologists categorized 40 liver biopsies of patients with nonalcoholic fatty liver disease (NAFLD) according to their own experience. In a second reading session, each pathologist reclassified the same slides by using the FLIP algorithm and SAF score, blinded to their first evaluation. The experiment was repeated with two different groups of pathologists at varying levels of training in liver pathology. The percentage of biopsy interpretation concordant with reference evaluation increased from 77% to 97% in Group 1 and from 42% to 75% in Group 2 after the use of the SAF score and FLIP algorithm. The strength of concordance in classification increased in Group 1 from moderate (kappa=0.54) to substantial (kappa=0.66) and from fair (kappa=0.35) to substantial (kappa=0.61) in Group 2 with application of the algorithm. With regard to the SAF score, concordance was substantial in Group 1 for steatosis (kappa=0.61), activity (kappa=0.75), and almost perfect for fibrosis (kappa=0.83 after pooling 1a, 1b, and 1c together into a single score F1). Similar trends were observed in Group 2 (kappa=0.54 for S, kappa=0.68 for A, and kappa=0.72 for F). Conclusion: The FLIP algorithm based on the SAF score should decrease interobserver variations among pathologists and are likely to be implemented in pathology practice.
引用
收藏
页码:565 / 575
页数:11
相关论文
共 39 条
[1]   FATTY LIVER HEPATITIS AND CIRRHOSIS IN OBESE PATIENTS [J].
ADLER, M ;
SCHAFFNER, F .
AMERICAN JOURNAL OF MEDICINE, 1979, 67 (05) :811-816
[2]   Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis [J].
Aithal, Guruprasad P. ;
Thomas, James A. ;
Kaye, Philip V. ;
Lawson, Adam ;
Ryder, Stephen D. ;
Spendlove, Ian ;
Austin, Andrew S. ;
Freeman, Jan G. ;
Morgan, Linda ;
Weeber, Jonathan .
GASTROENTEROLOGY, 2008, 135 (04) :1176-1184
[3]   The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD [J].
Angulo, Paul ;
Hui, Jason M. ;
Marchesini, Giulio ;
Bugianesi, Ellisabetta ;
George, Jacob ;
Farrell, Geoffrey C. ;
Enders, Felicity ;
Saksena, Sushma ;
Burt, Alastair D. ;
Bida, John P. ;
Lindor, Keith ;
Sanderson, Schuyler O. ;
Lenzi, Marco ;
Adams, Leon A. ;
Kench, James ;
Therneau, Terry M. ;
Day, Christopher P. .
HEPATOLOGY, 2007, 45 (04) :846-854
[4]   Simple Noninvasive Systems Predict Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease [J].
Angulo, Paul ;
Bugianesi, Elisabetta ;
Bjornsson, Einar S. ;
Charatcharoenwitthaya, Phunchai ;
Mills, Peter R. ;
Barrera, Francisco ;
Haflidadottir, Svanhildur ;
Day, Christopher P. ;
George, Jacob .
GASTROENTEROLOGY, 2013, 145 (04) :782-+
[5]  
[Anonymous], 2003, Statistical Methods for Rates and Proportions
[6]   An algorithm for the grading of activity in chronic hepatitis C [J].
Bedossa, P ;
Poynard, T .
HEPATOLOGY, 1996, 24 (02) :289-293
[7]   Sampling variability of liver fibrosis in chronic hepatitis C [J].
Bedossa, P ;
Dargère, D ;
Paradis, V .
HEPATOLOGY, 2003, 38 (06) :1449-1457
[8]   Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients [J].
Bedossa, Pierre ;
Poitou, Christine ;
Veyrie, Nicolas ;
Bouillot, Jean-Luc ;
Basdevant, Arnaud ;
Paradis, Valerie ;
Tordjman, Joan ;
Clement, Karine .
HEPATOLOGY, 2012, 56 (05) :1751-1759
[9]   A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis [J].
Belfort, Renata ;
Harrison, Stephen A. ;
Brown, Kenneth ;
Darland, Celia ;
Finch, Joan ;
Hardies, Jean ;
Balas, Bogdan ;
Gastaldelli, Amalia ;
Tio, Fermin ;
Pulcini, Joseph ;
Berria, Rachele ;
Ma, Jennie Z. ;
Dwivedi, Sunil ;
Havranek, Russell ;
Fincke, Chris ;
DeFronzo, Ralph ;
Bannayan, George A. ;
Schenker, Steven ;
Cusi, Kenneth .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (22) :2297-2307
[10]   Pathology of nonalcoholic fatty liver disease [J].
Brunt, Elizabeth M. .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2010, 7 (04) :195-203